Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Total Non-Current Liabilities (2018 - 2025)

X4 Pharmaceuticals' Total Non-Current Liabilities history spans 8 years, with the latest figure at $104.2 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 16.19% year-over-year to $104.2 million; the TTM value through Dec 2025 reached $104.2 million, down 16.19%, while the annual FY2025 figure was $104.2 million, 16.19% down from the prior year.
  • Total Non-Current Liabilities reached $104.2 million in Q4 2025 per XFOR's latest filing, up from $101.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $124.3 million in Q4 2024 to a low of $49.3 million in Q1 2022.
  • Average Total Non-Current Liabilities over 5 years is $81.4 million, with a median of $88.7 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 106.17% in 2023, then dropped 16.19% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $52.8 million in 2021, then rose by 10.67% to $58.4 million in 2022, then soared by 63.93% to $95.7 million in 2023, then increased by 29.84% to $124.3 million in 2024, then decreased by 16.19% to $104.2 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Total Non-Current Liabilities are $104.2 million (Q4 2025), $101.4 million (Q3 2025), and $100.7 million (Q2 2025).